![]() ![]() (2017) BP Control and Long-Term Risk of ESRD and Mortality. Ku, Elaine Gassman, Jennifer Appel, Lawrence J et al. Arterioscler Thromb Vasc Biol 37:1765-1769 (2017) APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). Am J Hypertens 31:665-671Ĭhen, Teresa K Appel, Lawrence J Grams, Morgan E et al. Juraschek, Stephen P Miller 3rd, Edgar R Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Affect Disord 229:1-13Īltman, Matthew C Whalen, Elizabeth Togias, Alkis et al. (2018) Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. J Allergy Clin Immunol Pract 6:1596-1603.e6Ĭoplan, Jeremy D Webler, Ryan Gopinath, Srinath et al. (2018) Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. Kattan, Meyer Bacharier, Leonard B O'Connor, George T et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Grams, Morgan E Sang, Yingying Ballew, Shoshana H et al. We therefore propose to conduct a pilot crossover medication treatment study consisting of an 8-week open treatment arm with DCS and an 8-week open treatment arm with CH, administered in randomized sequence with a 2-week washout period in 15 subjects currently suffering from DSM-IV depersonalization. However, based both on theoretical reasoning and case report data, there is reason to hypothesize that the NMDA partial glycine agonist D-cycloserine (DCS) and the 5HT2A and C antagonist cyproheptadine (CH) may have some efficacy in the treatment of DPD. Pharmacologists usually attempt to use a variety of marketed medications on the basis of the symptom and comorbidity profile of each individual patient. ![]() State-of-the-art psychopharmacologic treatment for the disorder is currently conducted without proven efficacy or systematic guidelines for any medication. Recent controlled trials of both SSRI and lamotrigine in DPD unfortunately proved negative. Currently, there are no approved pharmacological agents for the treatment of DPD. Depersonalization disorder (DPD) is a chronic, disabling psychiatric condition that is characterized by feelings of estrangement, detachment, and disconnection from one's sense of self. The institution listed is for the Center, which is not necessarily the institution for the investigator. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. ![]()
0 Comments
Leave a Reply. |